We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 483 Roundup: FDA Observes Quality Deficiencies at Six Drug Facilities
483 Roundup: FDA Observes Quality Deficiencies at Six Drug Facilities
FDA investigators observed inadequate investigations into bacterial contamination, documentation lapses and other quality deficiencies during inspections of six drug facilities.